Clonidine is NOT recommended for treating shortness of breath
Clonidine has no established role in the management of dyspnea and is not mentioned in any palliative care or dyspnea management guidelines. The evidence-based approach to shortness of breath prioritizes opioids (particularly morphine), with benzodiazepines for anxiety-associated dyspnea, and anticholinergics for secretion management 1.
Why Clonidine Should Not Be Used for Dyspnea
Lack of Evidence for Dyspnea
- No guideline support: The 2016 NCCN Palliative Care Guidelines comprehensively address dyspnea management without any mention of clonidine as a treatment option 1
- The American Thoracic Society statement on dyspnea management similarly does not include clonidine among recommended therapies 2
- Clonidine appears in guidelines only for hypertension 3, 4, ADHD 5, 6, hot flashes 7, and opioid tapering 8—never for respiratory symptoms
Respiratory Depression Concerns
Research evidence reveals concerning respiratory effects:
- Clonidine attenuates the ventilatory response to CO2, suggesting respiratory depressant effects 9
- It reduces both acute hypoxic response and hypoxic ventilatory decline 10
- Clonidine produces obstructive airway patterns associated with moderate oxygen desaturation 11
- While one study showed clonidine alone produces "little respiratory depression" in healthy volunteers 12, this does not translate to therapeutic benefit for dyspnea
Mechanism Makes It Unsuitable
Clonidine is a centrally-acting alpha-2 adrenergic agonist that:
- Lowers blood pressure and heart rate 3, 4
- Causes sedation, dry mouth, and drowsiness 7, 8
- Has no mechanism that would relieve the sensation of breathlessness
- One study showed it decreased susceptibility to central apnea 13, but this is irrelevant to symptomatic dyspnea relief
What SHOULD Be Used for Shortness of Breath
First-Line Pharmacologic Treatment
Opioids are the evidence-based first-line treatment 1:
- Morphine has the most extensive investigation for dyspnea
- For patients already on chronic opioids: consider a 25% dose increase
- Nebulized or subcutaneous fentanyl and oxycodone are alternatives
Adjunctive Pharmacologic Options
- Benzodiazepines: Only if dyspnea is associated with anxiety (beneficial effect is small) 1
- Anticholinergics for secretions: Glycopyrrolate, scopolamine, atropine, or hyoscyamine when excessive secretions contribute to dyspnea 1
Non-Pharmacologic Interventions
- Handheld fan directed at the face: Proven effective in randomized trials 1
- Supplemental oxygen: For hypoxemic patients, though room air may be equally effective for refractory dyspnea 1
- BiPAP or high-flow oxygen: May temporarily improve symptoms in selected patients 1
Common Pitfall to Avoid
Do not confuse clonidine's use in other conditions (hypertension, ADHD, opioid withdrawal) with any role in dyspnea management. The drug's sedative and respiratory depressant properties make it potentially harmful rather than helpful for breathlessness.